Adalimumab is a recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases. Check for active clinical trials using this agent.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company
in 2023, NO price increase on ProteoGenix products, to support your discoveries💥